Filing Flows › Onconetix (ONCO) › Q4 2024
Onconetix (ONCO) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Jun 2, 2025
Onconetix (ONCO) reported revenue of $712K for the fourth quarter 2024 (Q4 2024) and +75% from the quarter before.
Onconetix, Q4 2024: revenue $712K, net loss $29.4M, operating cash flow −$918K. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $712K | +75% | — |
| Operating profit | −$29.1M | — | — |
| Net earnings | −$29.4M | — | — |
| Operating cash flow | −$918K | — | — |
What changed
Revenue was $712K in Q4 2024, up 75% from the previous quarter.
Gross margin was 92.7%. Operating costs exceeded revenue by $29.1M, an operating margin of -4093.7%. The quarter ended with a net loss of $29.4M, wider than the previous quarter's $3.8M loss.
Operating cash flow was −$918K. Non-cash charges added back $119K of depreciation and amortization and $340K of share-based compensation. Working capital and other items added $28.1M. Capital expenditures of $4K exceeded it, leaving free cash flow of −$922K.
Questions
What was Onconetix's revenue in the fourth quarter 2024?
Onconetix (ONCO) reported revenue of $712K for the fourth quarter 2024 (Q4 2024) and +75% from the quarter before.
Source: Onconetix 10-K on SEC EDGAR.